SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Wahl DG, Bounameaux H, de Moerloose P, Sarasin FP. Prophylactic antithrombotic therapy for patients with systemic lupus erythematosus with or without antiphospholipid antibodies: do the benefits outweigh the risks? A decision analysis. Arch Intern Med 2000; 160: 20428.
  • 2
    Love PE, Santoro SA. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders: prevalence and clinical significance. Ann Intern Med 1990; 112: 68298.
  • 3
    Qushmaq K, Esdaile J, Devine DV. Thrombosis in systemic lupus erythematosus: the role of antiphospholipid antibody. Arthritis Care Res 1999; 12: 2129.
  • 4
    Kiraz S, Ertenli I, Benekli M, Haznedaroglu IC, Calguneri M, Celik I et al. Clinical significance of haemostatic markers and thrombomodulin in systemic lupus erythematosus: evidence for a prothrombotic state. Lupus 1999; 8: 73741.
  • 5
    Petri M. Thrombosis and systemic lupus erythematosus: the Hopkins Lupus Cohort perspective. Scand J Rheumatol 1996; 25: 1913.
  • 6
    Belmont HM, Abramson SB, Lie JT. Pathology and pathogenesis of vascular injury in systemic lupus erythematosus: interactions of inflammatory cells and activated endothelium. Arthritis Rheum 1996; 39: 922.
  • 7
    Coppola A, Davi G, de Stefano V, Mancini FP, Cerbone AM, Di Minno G. Homocysteine, coagulation, platelet function, and thrombosis. Semin Thromb Hemost 2000; 26: 24354.
  • 8
    Blom HJ. Consequences of homocysteine export and oxidation in the vascular system. Semin Thromb Hemost 2000; 26: 22732.
  • 9
    Petri M, Roubenoff R, Dallal GE, Nadeau MR, Selhub J, Rosenberg IH. Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus. Lancet 1996; 348: 11204.
  • 10
    De Stefano V, Rossi E, Paciaroni K, Leone G. Screening for inherited thrombophilia: indications and therapeutic implications. Haematologica 2002; 87: 1095108.
  • 11
    Lane DA, Mannucci PM, Bauer KA, Bertina RM, Bochkov NP, Boulyjenkov V, et al. Inherited thrombophilia: part 1. Thromb Haemost 1996; 76: 65162.
  • 12
    Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 12717.
  • 13
    Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997; 40: 1725.
  • 14
    Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999; 42: 130911.
  • 15
    Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Eng J Med 1998; 338: 104250.
  • 16
    Brandt JT, Triplett DA, Alving B, Scharrer I, and the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Criteria for the diagnosis of lupus anticoagulants: an update. Thromb Haemost 1995; 74: 118590.
  • 17
    Harris EN. Special report: the Second International Anti-Cardiolipin Standardization Workshop/the Kingston Anti-Phospholipid Antibody Study (KAPS) group. Am J Clin Pathol 1990; 94: 47684.
  • 18
    Torresan M, Machado TF, Siquiera LH, Ozelo MC, Arruda VR, Annichino-Bizzacchi JM. The impact of the search for thrombophilia risk factors among antiphospholipid syndrome patients with thrombosis. Blood Coagul Fibrinolysis 2000; 11: 67982.
  • 19
    Long AA, Ginsberg JS, Brill-Edwards P, Johnston M, Turner C, Denburg JA, et al. The relationship of antiphospholipid antibodies to thromboembolic disease in systemic lupus erythematosus: a cross-sectional study. Thromb Haemost 1991; 66: 5204.
  • 20
    Amoroso A, Mitterhofer AP, Del Porto F, Garzia P, Ferri GM, Galluzzo S, et al. Antibodies to anionic phospholipids and anti-beta2-GPI: association with thrombosis and thrombocytopenia in systemic lupus erythematosus. Hum Immunol 2003; 64: 26573.
  • 21
    Musial J, Swadzba J, Szczeklik A. Adaptative mechanisms counterbalancing enhanced thrombinogenesis in antiphospholipid syndrome. Thromb Res 1998; 90: 934.
  • 22
    Tomas JF, Alberca I, Tabernero MD, Cordero M, Del Pino-Montes J, Vicente V. Natural anticoagulant proteins and antiphospholipid antibodies in systemic lupus erythematosus. J Rheumatol 1998; 25: 5762.
  • 23
    Roubey RA. Autoantibodies to phospholipid-binding plasma proteins: a new view of lupus anticoagulants and other “antiphospholipid” autoantibodies. Blood 1994; 84: 285467.
  • 24
    Oosting JD, Derkesen RH, Bobbink IW, Hackeng TM, Bouma BN, De Groot PG. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: an explanation for their pathogenic mechanism? Blood 1993; 81: 261825.
  • 25
    Fijnheer R, Roest M, Haas FJ, De Groot PG, Derksen RH. Homocysteine, methylenetetrahydrofolate reductase polymorphism, antiphospholipid antibodies, and thromboembolic events in systemic lupus erythematosus: a retrospective cohort study. J Rheumatol 1998; 25: 173742.
  • 26
    Selhub J, Jacques PF, Wilson PW, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993; 270: 26938.
  • 27
    Refai TM, Al-Salem IH, Nkansa-Dwamena D, Al-Salem MH. Hyperhomocysteinaemia and risk of thrombosis in systemic lupus erythematosus patients. Clin Rheumatol 2002; 21: 45761.
  • 28
    Hampton KK, Preston FE, Greaves M. Resistance to activated protein C [letter]. N Engl J Med 1994; 331: 130.
  • 29
    Nojima J, Kuratsune H, Suehisa E, Kawasaki T, Machii T, Kitani T, et al. Acquired activated protein C resistance is associated with the co-existence of anti-prothrombin antibodies and lupus anticoagulant activity in patients with systemic lupus erythematosus. Br J Haematol 2002; 118: 57783.
  • 30
    De Stefano V, Martinelli I, Mannucci PM, Paciaroni K, Chiusolo P, Casorelli I, et al. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. N Engl J Med 1999; 341: 8016.
  • 31
    Martinelli I, Bucciarelli P, Margaglione M, De Stefano V, Castaman G, Mannucci PM. The risk of venous thromboembolism in family members with mutations in the genes of factor V or prothrombin or both. Br J Haematol 2000; 111: 12239.
  • 32
    Ruiz-Arguelles GJ, Garces-Eisele J, Alarcon-Segovia D, Ruiz-Arguelles A. Activated protein C resistance phenotype and genotype in patients with primary antiphospholipid syndrome. Blood Coagul Fibrinolysis 1996; 7: 3448.
  • 33
    Aznar J, Villa P, Espana F, Estelles A, Grancha S, Falco C. Activated protein C resistance phenotype in patients with antiphospholipid antibodies. J Lab Clin Med 1997; 130: 2028.
  • 34
    Picillo U, De Lucia D, Palatiello E, Scuotto A, Marcialis MR, Pezzella S, et al. Association of primary antiphospholipid syndrome with inherited activated protein C resistance. J Rheumatol 1998; 25: 12324.
  • 35
    Male C, Mitchell L, Julian J, Vegh P, Joshua P, Adams M, et al. Acquired activated protein C resistance is associated with lupus anticoagulants and thrombotic events in pediatric patients with systemic lupus erythematosus. Blood 2001; 97: 8449.
  • 36
    Ehrenforth S, Radtke KP, Scharrer I. Acquired activated protein C-resistance in patients with lupus anticoagulants. Thromb Haemost 1995; 74: 7978.
  • 37
    Potzsch B, Kawamura H, Preissner KT, Schmidt M, Seelig C, Muller-Berghaus G. Acquired protein C dysfunction but not decreased activity of thrombomodulin is a possible marker of thrombophilia in patients with lupus anticoagulant. J Lab Clin Med 1995; 125: 5665.
  • 38
    Svensson PJ, Zoller B, Dahlback B. Evaluation of original and modified APC-resistance tests in unselected outpatients with clinically suspected thrombosis and in healthy controls. Thromb Haemost 1997; 77: 3325.
  • 39
    Petri M. Management of thrombosis in antiphospholipid antibody syndrome. Rheum Dis Clin North Am 2001; 27: 63342.
  • 40
    Alarcon-Segovia D. Antiphospholipid syndrome within systemic lupus erythematosus. Lupus 1994; 3: 28991.
  • 41
    Roubey RA. Systemic lupus erythematosus, hypercoagulable states, and antiphospholipid antibodies. Arthritis Care Res 1999; 12: 1556.
  • 42
    Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 1998; 338: 104250.